5 completed, 2 unknown, 1 active not recruiting, 1 recruiting. 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 5, Unknown 2, Active not recruiting 1, Recruiting 1 |
Follow Blue Earth Diagnostics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 18F-FLUC PET/MR in Patients With Brain Mets F-Fluciclovine radiotracer - Brain Metastasis, Radiation Therapy | Phase 3 | Recruiting | University of Wisconsin, Madison | 30 | 2024-01-10 | 2026-06-22 |
| Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management rhPSMA-7.3 (18F) - Prostate Cancer | Phase 3 | Unknown | MidLantic Urology | 113 | 2023-04-27 | 2024-05-24 |
| Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent, PET MRI Imaging - Prostate Cancer | Phase 3 | Active not recruiting | NYU Langone Health | 26 | 2023-01-31 | 2026-03-25 |
| 18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy PET imaging with 18F fluciclovine - Grade III or Grade IV Glioma | Phase 3 | Unknown | Nicole Hill | 30 | 2022-08-24 | 2022-10-27 |
| Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases 18F fluciclovine - Brain Metastases | Phase 3 | Completed | Blue Earth Diagnostics | 151 | 2020-10-26 | 2025-08-28 |
| Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence rhPSMA-7.3 (18F) Injection, Positron emission tomography scan - Prostate Cancer | Phase 3 | Completed | Blue Earth Diagnostics | 391 | 2020-05-04 | 2025-09-22 |
| Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer. rhPSMA-7.3 (18F) Injection, Positron Emission Tomography scan - Prostate Cancer | Phase 3 | Completed | Blue Earth Diagnostics | 356 | 2020-03-02 | 2025-02-26 |
| 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment 18F-fluciclovine PET CT - Prostate Cancer | Phase 3 | Completed | Blue Earth Diagnostics | 221 | 2016-06-01 | 2019-01-28 |
| Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer 18F-Fluciclovine PET CT - Cancer of the Prostate | Phase 3 | Completed | Blue Earth Diagnostics | 104 | 2015-11-01 | 2019-10-07 |
Prostatic Neoplasms (6) · Disease (3) · Brain Neoplasms (2) · Lymphoma, Follicular (1) · Motor Activity (1)
Injections (2) · Positron-Emission Tomography (2) · fluciclovine F-18 (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · Magnetic Resonance Spectroscopy (1)
United States (8) · Finland (2) · Netherlands (2) · Germany (1) · United Kingdom (1)
Fergus Gleeson, FRCP FRCR (1) · Herbert Lepor, MD (1) · Laurence Belkoff, DO, FACOS (1) · Michael Veronesi, MD, PhD (1) · Peter Gardiner, MB ChB, MRCP, FFPM (1) · Poonam Choudhary, PhD (1) · Umar Mahmood, MD, PhD (1)
PMID 37121865, PMID 31216198, PMID 31624865, PMID 32068113, PMID 34081125, PMID 37414702, PMID 38782456, PMID 42850466